Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 166

The DOI matches its Crossref record.

Molecular Remission After Allogeneic or Autologous Transplantation of Hematopoietic Stem Cells for Multiple Myeloma

Martinelli, Giovanni, Terragna, Carolina, Zamagni, Elena, Ronconi, Sonia, Tosi, Patrizia, Lemoli, Roberto M., Bandini, Giuseppe, Motta, Maria Rosa, Testoni, Nicoletta, Amabile, Marilina, Ottaviani, Emanuela, Vianelli, Nicola, de Vivo, Antonio, Gozzetti, Alessandro, Tura, Sante, Cavo, Michele · 2000 · Journal of Clinical Oncology

Abstract

PURPOSE: To assess the clinical relevance of minimal residual disease (MRD) in patients with multiple myeloma (MM), 50 patients were monitored while they were in complete clinical remission (CCR) after autologous or allogeneic stem-cell transplantation. PATIENTS AND METHODS: Stringent molecular monitoring using clonal markers based on rearranged immunoglobulin heavy-chain genes was performed in 44 of 50 MM patients in CCR. Molecular clinical remission (MCR) was defined as more than one consecutive negative polymerase chain reaction (PCR) test result. RESULTS: Twelve (27%) of 44 molecularly monitored patients achieved MCR; four of the 12 became PCR-positive, and one of these four relapsed. In comparison with patients who did not achieve MCR, patients who achieved MCR had a significantly lower relapse rate (41% v 16%; P < .05) and longer relapse-free survival (35 v 110 months; P < .005). Fourteen of 26 patients in CCR who had received allografts were evaluated on a molecular basis: seven (50%) of the 14 achieved MCR and did not relapse; one of the seven remaining patients relapsed. Thirty of 47 patients in CCR who received autografts were evaluated on a molecular basis: five (16%) of the 30 achieved MCR; two of these five became PCR-negative, and one of these two relapsed. Ten of the 25 remaining patients later relapsed. For these nonrandomized groups, the higher MCR rate after allograft procedures was statistically significant (P < .01; Fisher’s exact test). CONCLUSION: MCR can be obtained in a relatively high proportion of MM patients who have achieved CCR after undergoing allograft procedures and in a smaller fraction of patients after undergoing autograft procedures. In approximately one fourth of MM patients who achieve CCR after transplantation, it may be possible to keep the disease burden constantly below the PCR threshold. Because MCR was associated with prolonged relapse-free survival, these patients could have a relatively favorable clinical outcome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2000.18.11.2273

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 166

Metadata

Authors
Martinelli, G., Terragna, C., Zamagni, E., Ronconi, S., Tosi, P., Lemoli, R. M., Bandini, G., Motta, M. R., Testoni, N., Amabile, M., Ottaviani, E., Vianelli, N., de Vivo, A., Gozzetti, A., Tura, S., & Cavo, M.
Venue
Journal of Clinical Oncology
Published
2000-06-11
Volume
18
Issue
11
Pages
2273-2281
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2247986604
Cited by
166
References
0
FWCI
6.11
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular Remission After Allogeneic or Autologous Transplantation of Hematopoietic Stem Cells for Multiple Myeloma. https://app.cochat.ai/papers/10.1200/jco.2000.18.11.2273
The paper
Martinelli, G., Terragna, C., Zamagni, E., Ronconi, S., Tosi, P., Lemoli, R. M., Bandini, G., Motta, M. R., Testoni, N., Amabile, M., Ottaviani, E., Vianelli, N., de Vivo, A., Gozzetti, A., Tura, S., & Cavo, M. (2000). Molecular Remission After Allogeneic or Autologous Transplantation of Hematopoietic Stem Cells for Multiple Myeloma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2000.18.11.2273

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.